Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The muscarinic acetylcholine receptor M4 (CHRM4) is a G protein-coupled receptor that functions as an inhibitory autoreceptor for acetylcholine. It is highly expressed in the forebrain, particularly in the striatum, and plays a role in regulating neurotransmitter release and modulating dopaminergic neurotransmission. CHRM4 is implicated in several neurological disorders, including Parkinson's disease, schizophrenia, and Alzheimer's disease, and is a potential therapeutic target for these conditions. Drug development efforts focus on achieving subtype-selective modulation to minimize off-target cholinergic side effects.
Gi/o-coupled receptor activation; inhibits adenylate cyclase; modulates potassium channels; inhibits acetylcholine release.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Muscarinic Acetylcholine Receptor M4 (CHRM4).